Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Escape Therapeutics Inc. currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 2 distinct examiners and 2 distinct art units. This suggests a broader technical scope for the company's current patent filings within the biotech sector.
FISCHER, JOSEPH is the busiest examiner for the company, with 1 pending office action. Since there are 2 distinct examiners involved in the 2 pending office actions, the company is engaging with multiple points of review at the USPTO. The presence of 2 distinct art units indicates that the prosecution involves different specialized examination teams.
Because the 2 pending office actions are split between 2 distinct art units, the company is likely pursuing diverse technical claims within the Biotechnology & Pharmaceuticals sector. Practitioners must coordinate responses that are consistent across these different examination groups. The involvement of FISCHER, JOSEPH as one of the 2 distinct examiners highlights the need for specialized attention to individual examiner tendencies.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FISCHER, JOSEPH | 1 | 43.4% | +45.6% |
| MARTINEZ, TARA L | 1 | 62.6% | +65.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17799201 | MELANOMA THERAPEUTICS | MARTINEZ, TARA L | 61d |
| 18249521 | ENHANCED SKIN PERMEATION OF A NOVEL PEPTIDE VIA STRUCTURAL MODIFICATION, CHEMICAL ENHANCEMENT, AND MICRONEEDLES | FISCHER, JOSEPH | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18249521 | ENHANCED SKIN PERMEATION OF A NOVEL PEPTIDE VIA STRUCTURAL MODIFICATION, CHEMICAL ENHANCEMENT, AND MICRONEEDLES | FISCHER, JOSEPH | 1658 | §102§103§112DP | Non-Final OA | — | Pending | Apr 18, 2023 |
| 17799201 | MELANOMA THERAPEUTICS | MARTINEZ, TARA L | 1654 | §103 | Non-Final OA | 61d | Pending | Aug 11, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial